Fill & Finish services

Fill & Finish services
Product Description

Our aseptic Fill & Finish services, in combination with our other services or offered as a stand--alone project or in combination with other services, providee a seamless transition from Drug Substance Manufacturing drug substance production to the Ffinal pProduct deliveryrelease. Our solutions cover every part of the Fill & Finish process, from vials sterilizationdepyrogenation, through automatic filling vial filling s from format 2R to 100R, capping and stoppering to secondary packaging and serialization. Full integration with Mabion’s other Mabion’s operationsservice portfolio allows yyou ou to benefit from a streamlined end-to-end service package that includes everything from upstream and downstream processingdevelopment, clinical to commercial GMP manufacturing to the final product release. This approach mitigates delays and ensures consistent quality, while reducing costs. With Mabion as a partner, you can stay confident that your product will reach its destinat...

Mabion SA

  • PL
  • 2023
    On CPHI since
  • 3
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
Primary activities
Analytical Services
Biopharmaceutical
Contract Manufacturer
Intermediates Manufacturer
Specifications
  • Selling Points
    Guarantee/Warranty; Place of Origin; Price; Prompt Delivery; Quality Service; Reputation; Sustainability
  • Model
    Service
  • Supplied from
    Poland
  • Measured In
    Container

Mabion SA

  • PL
  • 2023
    On CPHI since
  • 3
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
Primary activities
Analytical Services
Biopharmaceutical
Contract Manufacturer
Intermediates Manufacturer

More Products from Mabion SA (4)

  • MabionCD20

    Product MabionCD20

    This is our most advanced in-house project. A MabThera/Rituxan (rituximab) biosimilar drug, whose efficacy and safety were clinically confirmed. It is the first such advanced drug developed in Poland. We are currently at the final stage of works aimed at marketing the drug in Europe and the United States.
  • Analytical Services

    Product Analytical Services

    Mabion offers a extensive suite of Analytical Services to ensure safety, efficacy and quality of your biologic product. Our portfolio includes development, optimization and validation of analytical methods, as well as stability studies, GMP release testing and in-depth drug characterization. In addition to...
  • Drug Substance Manufacturing services

    Product Drug Substance Manufacturing services

    Mabion offers advanced Drug Substance Manufacturing services encompassing various types of biologics, antibodies (including multi-specifics and ADC), fusion proteins, enzymes and vaccine antigens. Our state-of-the-art facilities offer 25L – 8000L scale GMP DS batch size for mammalian and insect cell line p...
  • Process Development services

    Product Process Development services

    Our early phase Process Development services focus on bridging the gap between lab scale and GMP manufacturing, ensuring robust scalability and outstanding productivity. In addition, based on our almost 20 years of experience, our late stage Process Development services design and execute process transfer ...

Mabion SA resources (2)

  • News Development and regulation of veterinary monoclonals

    Simarly to the drugs for human use, veterinary drugs must pass a strict registration procedure, both in the EU and US realms – sponsoring companies must present comprehensive evidence that they are safe and effective for use. While in the EU veterinary mAbs are approved by the EMA, in the U.S. these products are evaluated either by FDA or USDA (U.S. Department of Agriculture), depending on the intended indication.
  • Brochure Mabion - Your Biologics CDMO

    A description of Mabion's CDMO offering